REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
07/04/2026
Back to search
Official data from USPTO
DUPIXENT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/04/2026
Trademark type
Combined
Nice classes
5
Filing date
10/13/2016
Registration date
07/04/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/04/2023
Last transaction
07/04/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
03
Owner location
Paris, FR
Examiner
STINSON, JENNIFER ELLE
Law office
N30
Current location
TMO LAW OFFICE 121
Mark description
The mark consists of the word "DUPIXENT" in brown to the left of the design of four arrows pointing right. The first arrow is yellow and connected to the second orange arrow at the bottom by a dark orange line. The third arrow is dark green and is connected to the fourth light green arrow at the top by a green line. White represents background and is not claimed as a feature of the mark.
Holders and representatives
Holders
S. B. (pessoa física)
S. B. (pessoa física)
Representatives
Karen Lim FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of allergies and allergic diseases and disordersautoimmune diseases and disordersdermatological diseases and disordersdamaged skin and tissuesgastrointestinal diseases and disordersinflammation and inflammatory diseases and disordersrespiratory diseases and disorders
Publications
History of USPTO decisions and trademark events.
33 publications found
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
11/04/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
11/04/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/04/2023
ES8R
TEAS SECTION 8 RECEIVED
07/06/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/04/2022
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
01/08/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/10/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/04/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/18/2017
PUBO
PUBLISHED FOR OPPOSITION
04/18/2017
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
04/05/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/29/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/16/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/24/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/24/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/15/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/12/2017
GNSL
LETTER OF SUSPENSION E-MAILED
02/12/2017
CNSL
SUSPENSION LETTER WRITTEN
02/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/10/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/10/2017
ALIE
ASSIGNED TO LIE
02/07/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/24/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/02/2016
GNRT
NON-FINAL ACTION E-MAILED
11/02/2016
CNRT
NON-FINAL ACTION WRITTEN
11/02/2016
DOCK
ASSIGNED TO EXAMINER
11/02/2016
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/19/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/18/2016
NWAP
NEW APPLICATION ENTERED
10/17/2016
Continuous trademark protection
Get notified about every new filing that threatens DUPIXENT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.